… have rarely been used, which is astonishing because imatinib-resistant cell … imatinib-resistant
BCR-ABL1 positive cell lines. Five out of 19 Ph+ cell lines (26%) were resistant to imatinib. …

… and BCR-ABL1, there are several breakpoints in BCR that produce distinct BCR-ABL1 isoforms…
In patients with CML, the most common BCR-ABL1 isoform results from the fusion of BCR …

… In summary, sensitive detection of resistant mutations after imatinib resistance by mass
spectrometry was highly predictive of their subsequent expansion and treatment failure if the …

… been performed after assessment of BCR-ABL1 KD mutation status by SS, so no patient
positive for the T315I mutation by SS at the time of imatinib resistance is included in this series. …

… and ABL1 inhibitors have been developed and entered into clinical trials. These inhibitors
appear effective in inhibiting most of the mutant BCR-ABL1 molecules that are resistant to IM. …

… to the development of other TKIs, the so-called second- and third-generation TKIs, that are
more potent than imatinib in the inhibition of unmutated as well as mutant p210 BCR-ABL1 . …

… Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) … IM resistance often results from
a secondary mutation in BCR-… BCR-ABL, and the basis of such BCR-ABL–independent IM …

… BCR-ABL1 mutation status in CML with imatinib resistance should be supplemented by NGS
to identify underrepresented BCR-ABL1 … types possibly related to imatinib treatment failure. …

… We suggest that the association of BCR-ABL1 35INS with imatinib resistance as shown
here calls for a re-evaluation of the possible mechanism of resistance associated with …

… initial response (secondary resistance). Based on … BCR-ABL1 mutations are detected with
a frequency ranging from 12% to 63% in CML patients who experienced imatinib resistance …